Results 41 to 50 of about 1,763 (188)

Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis

open access: yes, 2023
The concept of oligoprogression reflects a situation where a limited number of metastatic tumor sites have progressed and other metastatic sites are under control with current systemic therapy.
Burcak Karaca   +7 more
core   +1 more source

The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review

open access: yesCurrent Oncology, 2023
Stereotactic body radiotherapy (SBRT) has emerged as a technique to treat oligoprogressive sites among patients with breast cancer who are otherwise doing well on systemic therapy. This study systematically reviewed the efficacy and safety of SBRT in the
Bernie Yan   +4 more
doaj   +1 more source

Successful treatment of induced oligometastasis and repeated oligoprogression of advanced lung adenocarcinoma with immunotherapy and radiotherapy

open access: yesThoracic Cancer, 2022
Highly active and durable systemic therapies such as targeted therapy and immunotherapy can convert widespread metastatic disease into oligometastatic status, for which metastasis‐directed local intervention can control and potentially prolong survival ...
Ho Young Lee   +6 more
doaj   +1 more source

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer

open access: yesFrontiers in Oncology, 2020
Purpose/Objective: Oligometastatic disease (OMD) and oligoprogressive disease (OPD) describe tumor states with a limited metastasization. In contrast to other disease states, treatment of OMD or OPD has not yet become common for breast cancer.
Fabian Weykamp   +35 more
doaj   +1 more source

Checkpoint inhibitors in non-small cell lung carcinoma therapy for progression to the brain (clinical observation) [PDF]

open access: yes, 2022
The development of a new area of antitumor drug therapy, immunotherapy using immune checkpoint inhibitors targeting PD-1/PD-L1, has significantly changed approaches to the treatment of advanced non-small cell lung cancer (NSCLC).
E. A. Kalabanova   +9 more
core   +1 more source

[Oligoprogression].

open access: yesStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2015
Hintergrund: Erlotinib ist beim nichtkleinzelligen Lungenkarzinom (NSCLC) in der metastasierten Situation zugelassen nach dem Versagen der Erstlinien-Chemotherapie, unabhängig vom EGFR-Mutationsstatus. Die vorliegende Phase-II-Studie untersuchte den Stellenwert einer lokalen körperstereotaktischen Bestrahlung simultan zur Erlotinib-Therapie nach ...
openaire   +5 more sources

Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma

open access: yesCurrent Oncology, 2023
Stereotactic ablative radiotherapy (SABR) has challenged the conventional wisdom surrounding the radioresistance of renal cell carcinoma (RCC). In the past decade, there has been a significant accumulation of clinical data to support the safety and ...
Rohit K. Raj   +4 more
doaj   +1 more source

Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease [PDF]

open access: yesTranslational Lung Cancer Research, 2018
Stage IV non-small cell lung cancer (NSCLC) exists on a spectrum, with a subset of patients presenting with oligometastatic disease involving only a limited number of distant sites. For these patients, local consolidative therapy (LCT) has been demonstrated to improve outcomes through ablation or cytoreduction of metastatic disease, as shown in an ...
Matthew S, Ning   +3 more
openaire   +2 more sources

Acute Lymphopenia and Recovery With Prophylactic Pelvic Nodal Radiotherapy in Oligometastatic Prostate Cancer: Interim Results From the Prospective PROLONG2 Cohort

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Prophylactic pelvic nodal radiotherapy (PRT) aims to eradicate occult pelvic nodal disease in oligometastatic prostate cancer but increases lymphocyte exposure. Its early hematologic safety and lymphocyte recovery when added to radiotherapy to the prostate/prostate region and all imaging‐visible metastases remain uncertain.
Xin Qi   +13 more
wiley   +1 more source

Molecular Mechanisms and Therapeutic Advances in KRAS G12C‐Mutant Non‐Small Cell Lung Cancer: Toward Mechanism‐Guided Longitudinal Management

open access: yesCancer Innovation, Volume 5, Issue 5, October 2026.
This review summarizes the molecular mechanisms, clinical development, resistance patterns, and emerging treatment strategies of KRAS G12C‐mutated non‐small cell lung cancer, with emphasis on approved inhibitors, combination approaches, next‐generation agents, and future directions from both global and Chinese perspectives.
Haiying Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy